664 related articles for article (PubMed ID: 21306819)
21. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
[TBL] [Abstract][Full Text] [Related]
22. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
23. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Yuasa T; Urakami S; Yamamoto S; Yonese J; Nakano K; Kodaira M; Takahashi S; Hatake K; Inamura K; Ishikwa Y; Fukui I
Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
[TBL] [Abstract][Full Text] [Related]
24. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
26. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
28. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
29. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
30. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
[TBL] [Abstract][Full Text] [Related]
32. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
Thiam R; Fournier LS; Trinquart L; Medioni J; Chatellier G; Balvay D; Escudier B; Dromain C; Cuenod CA; Oudard S
Ann Oncol; 2010 May; 21(5):936-41. PubMed ID: 19889607
[TBL] [Abstract][Full Text] [Related]
33. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Grünwald V; Seidel C; Fenner M; Ganser A; Busch J; Weikert S
Br J Cancer; 2011 Nov; 105(11):1635-9. PubMed ID: 22033275
[TBL] [Abstract][Full Text] [Related]
34. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
35. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
37. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V
Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518
[TBL] [Abstract][Full Text] [Related]
38. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
39. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
[TBL] [Abstract][Full Text] [Related]
40. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
